Custom Search

Search Mad Money Fund Blog

Are You Buying Jim Cramer's Get Rich Carefully Book ?

Share Stock Picks

Sunday, February 21, 2010

Best stocks to buy this week ! ( Level 3 ) LVLT , ( XenoPort ) XNPT .....

1. Level 3 Communications (LVLT: 1.58 +0.13 +8.97%) / target 2.25 - Shares of Level 3 Communications rose 10% to $1.58 per share. The technical chart shows the stock is in a strong bull market both 50 day and 200 day moving average rising and MACD above signal. This is a good stock to own for the long term. Keep LVLT on your radar for Monday.Level 3 Communications, Inc. (Level 3) through its operating subsidiaries, is primarily engaged in the communications business. Level 3 is a facilities-based provider of a range of integrated communications services. As of December 31, 2008, the Company had approximately 77,000 intercity route miles in North America and Europe, connecting 23 countries. As of December 31, 2008, the Company had approximately 125 markets having metropolitan fiber networks containing approximately 27,000 route miles in the United States and Europe, and approximately 7,900 traffic aggregation points and buildings the aggregate. The Company's reportable segments include communications and coal mining. On June 5, 2008, Level 3 completed the sale of its Vyvx advertising distribution business to DG FastChannel, Inc.Short covering will boost this stock followed by improvements to earnings (which will still be poor) then someone will swoop up the wonde (assetts)r that this company holds and get rid of the managment who couldn't find there way home from a block away.someone else will buy them and put them to use. Infrastructure, Obama, Bandwidth demand, FIOS. Going up.The best thing that could happen to Level 3 would be for AT&T to buy them out, then we might make some real money.
Bplay - BlackBerry Games, Themes, and More
2.XenoPort, Inc.
(Public, NASDAQ:XNPT) 8.38 a share / target price 18.00
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The Company focuses on development and commercialization efforts on potential treatments of central nervous system (CNS), disorders. Its product candidate, XP13512, known in the United States by the trade name Solzira (gabapentin enacarbil) Extended Release Tablets, is being developed for the treatment of a number of CNS disorders. During the year ended December 31, 2008, XP13512 completed a Phase IIa clinical trial for the management of post-herpetic neuralgia (PHN), in the United States. a biopharmaceutical company focused on nutrient transport mechanisms, saw its shares cut in half earlier this week after receiving a response letter from the FDA detailing additional questions that preclude the approval of its NDA in its current form. However, shares recouped about 20% of their losses during today’s session.
GameFly - Animated LogoIn the complete response letter, the FDA indicated that a preclinical finding of pancreatic acinar cell tumors in rats was sufficient concern to preclude approval of Horizant for RLS at this time. The FDA acknowledged that similar findings were known for gabapentin at the time of its approval for refractory epilepsy, but concluded that the seriousness and severity justified the risk.oversold ,after XenoPort's remarkable 66% one day drop. Following ZZLangerhans who provides good reason for hope. Playing the bump here...he pancreatic tumor concern was never brought up by any analyst or journalist during the development of Solzira, again to the best of my knowledge. The upshot of all this is that Xenoport has a strong chance for a comeback against this FDA concern, and will receive quite a lot of support here. Whether or not they are eventually successful, the magnitude of the destruction indicates a strong likelihood of rebound to at least the 12 level within the next few months. As a back-up plan, the company has several other drugs in early development and sufficient funds to progress them into late stage trials, although there is nothing tremendously exciting at this point. And finally, the company does have a patented and unique platform of drug technology that improves bio availability of medications utilizing nutrient transporters in the GI tract. This is a substantial asset that may eventually make them a buyout candidate should they accept that route.
In summary, this is my pitch for buying Xenoport below 8 on an overreaction to Solzira Complete Response. This is not my wholehearted MR.BEER® Home Brewing Kits. American's #1 Home Brewing System. Makes a great gift!endorsement of Xenoport the company and I would get the hell out with a substantial profit as these guys have shown a pattern of disappointing results and poor anticipation of FDA concerns.
Post a Comment